Industry landscapes
The companies, capital and talent shaping life sciences in Los Angeles. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
29 of 323 tracked companies have open roles.
124 of 323 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 263 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 40.8% of disclosed capital, while 61.6% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $262.48M | 23 | 20 |
| 2017 | $139M | 15 | 23 |
| 2018 | $366.2M | 24 | 18 |
| 2019 | $87.76M | 24 | 19 |
| 2020 | $191.6M | 21 | 17 |
| 2021 | $711.24M | 17 | 30 |
| 2022 | $594.01M | 8 | 20 |
| 2023 | $250.21M | 11 | 24 |
| 2024 | $255.41M | 1 | 17 |
| 2025 | $398.04M | 3 | 22 |
Share of all disclosed company funding.
296 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Wing2Wingfoundation and National Science Foundation and others.
Backed by Boxcar Partners and TGVP.
Backed by Catcher Technology.
Backed by .
Backed by Matrix Capital Management and Westlake Village Biopartners and others.
Backed by Westlake Village Biopartners and Citadel and others.
Backed by Deep Track Capital and Goldman Sachs Asset Management and others.
Backed by Goldman Sachs Asset Management and Deep Track Capital and others.
Backed by Arch Venture Partners and Google Ventures and others.
Participating investors were not recorded in this snapshot.
Participating investors were not recorded in this snapshot.
Backed by Catalio Capital Management and Bristol-Myers Squibb and others.
Backed by Renaissance Acquisition Holdings and Delta Dental.
Participating investors were not recorded in this snapshot.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 4 reporting entities from 16 eligible matches.
Sum of reporting-entity revenue; not Los Angeles market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 4 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 4 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| MannKind Corp ↗899460 | $349.0m | $5.9m | +1.7% | — | — |
| Puma Biotechnology ↗1401667 | $228.4m | $31.1m | +13.6% | — | — |
| Aadi Bioscience ↗1422142 | $7.1m | $-20.6m | -288.3% | — | — |
| Capricor Therapeutics ↗1133869 | $0.0m | $-105.0m | — | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Los Angeles companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
11 of the 323 companies on this page carry a measured traffic record (3.4%); these are the largest of those, by monthly visits. The median among them is 387,760 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Seedseed.com | 1,401,372 | 51 | 79.4% |
| O Positivopositiv.com | 1,179,319 | 43 | 92.9% |
| Dosedosedaily.co | 1,008,338 | 40 | 89.5% |
| Ritualritual.com | 800,377 | 51 | 76.1% |
| iRestore Laser Hair Growth Systemirestorelaser.com | 536,099 | 38 | 81% |
| Sequencing.comsequencing.com | 387,760 | 41 | 74.1% |
| HUM Nutritionhumnutrition.com | 314,947 | 44 | 73.2% |
| Stonehenge Healthstonehengehealth.com | 201,742 | 31 | 75.7% |
| People Sciencepeoplescience.health | 146,539 | 18 | 97.4% |
| Leapcureleapcure.com | 47,342 | 27 | 93.3% |
Visits and authority are third-party web estimates, not company-reported figures.
8 of these companies (2.5%) publish at least one Android app — 10 apps in all, carrying 978.6K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Buenas TareasBuenasTareas | 851.1K | 2.7 | Education |
| Cubtale: Pregnancy & BabyCubtale | 50.7K | 4.5 | Parenting |
| dotFITdotFIT | 44.4K | 2.6 | Health & Fitness |
| Science 37 Clinical ResearchScience 37 | 23.7K | 3.5 | Health & Fitness |
| Chloe by People SciencePeople Science | 7.2K | 3.6 | Health & Fitness |
| dotFIT PlaySpandotFIT | 651 | — | Health & Fitness |
| iRESTOREiRestore Laser Hair Growth System | 412 | — | Lifestyle |
| BluHale PROMannKind Corp | 330 | — | Education |
| One Lambda TrainingOne Lambda | 51 | — | Education |
| iRESTORE BodyiRestore Laser Hair Growth System | 5 | — | Tools |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q3–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Tech | 3 | 882K | Buenas Tareas 851.1K | |
| Nutraceuticals Tech | 2 | 45.1K | dotFIT 44.4K | |
| Dermatology | 2 | 417 | iRESTORE 412 |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
19 companies hiring · $4.29B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Acelyrin’s $540 million raise—which was not just one of the largest of that year but among the biggest in the industry’s history—was understandably met with much excitement…
ANEUVO, a medical device startup developing neuromodulation implants for spinal cord injury, announced a $22 million Series C to accelerate clinical development of its implantable therapy.
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Immix Biopharma, Inc. ... net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $93.7 million.
Two startups — Pelage Pharmaceuticals and Veradermics — raised a combined $270 million to develop treatments for a common form of hair loss, known clinically as androgenetic alopecia.
Standard Dental Labs Inc. today announced that it has signed a binding agreement on November 4th, 2025 to acquire Dream Dentistry Labs, LLC.
Sitero, a technology-enabled CRO, acquired the AI assets and business of studyOS to embed autonomous, natural-language-driven trial workflow automation into its operations.
They quickly raised $4.3 million in seed funding.
The Plug Drink, a Los Angeles-based liver health supplement brand, raised $5 million in equity and debt in venture capital.
MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
Top 10 categories among 231 recorded events in the 24-month window.
9 companies with recorded IPO activity
IPO2 reports
Direct Listing1 reports
Follow-on Offering · NASDAQ3 reports
IPO · NASDAQ2 reports
IPO · Nasdaq6 reports
Follow-on Offering · NASDAQ3 reports
Follow-on Offering · NASDAQ3 reports
IPO · Upstream3 reports
1 tracked people moves
Appointment Chief Medical Officer
3 recorded customer wins
Customer: predictive oncologyTechBio
Customer: hitachi chemicalBiotechnology
Customer: nippon shinyakuPharmaceutical
2 companies with reported reductions
84 rolesCOVID-19 pandemic
7.0% rolesrestructuring plan
12 recorded events
granted marketing authorizationEuropean Commission
approved for extended adjuvant treatmentU.S. Food and Drug Administration
approved for combination with capecitabine for treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimensU.S. Food and Drug Administration
Orphan Drug designation grantedEuropean Medicines Agency
3 tracked suits
securities fraudClass Action ·
Wrongful termination for reporting clinical data issuesCivil · Filed
Reported company results in the recorded window.
Median across 20 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| gilead→Kite Pharma ↗ | Completed | 2026-03-04 | $11.9B |
| Kairos Pharma→Celyn Therapeutics, Inc. | Announced | 2026-03-02 | Not stated in snapshot |
| Teva Pharmaceutical Industries→Auspex Pharmaceuticals ↗ | 2026-02-10 | Not stated in snapshot | |
| Science 37→LifeSci Acquisition | Completed | 2026-01-01 | $235.0M |
| sitero→studyOS ↗ | 2025-12-22 | Not stated in snapshot | |
| Standard Dental Labs→Dream Dentistry Labs, LLC | Announced | 2025-11-04 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
440 postings in the preceding 12 months. The full 1,170-posting snapshot covers 30 employers.
20 tracked postings mention remote work.
328 postings specify a level.
Top skills across 1,170 tracked postings in the available jobs snapshot.
Median across 121 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Employees |
|---|---|
| Agilisium ↗ | 548 |
| MannKind Corp ↗ | 322 |
| Prolacta Bioscience ↗ | 314 |
| Puma Biotechnology ↗ | 193 |
| Ritual ↗ | 126 |
| ACELYRIN ↗ | 113 |
| Aadi Bioscience ↗ | 95 |
| Sanguine ↗ | 73 |
220 founders and chief executives across 165 companies.
Mannkind, ex-Amgen, ex-Bristol Myers Squibb, Massachusetts College of Pharmacy and Health Sciences, 2014
Ex- Global R&D, Abraxis Bioscience. Institute of Chemical Technology BS, University of Texas at Austin MS & Ph.D
Founder CELLerity Consulting, Visionary Venture Fund, ex-Allergan. Harvard University BSc 1979, University of Pennsylvania PhD 1985
Ex-Founder Nano Precision Medical. University of California, Berkeley PhD 2011
Intro, ex-Health Ade, ex-Gsk, University of Southern California - Marshall School of Business, 2013
Pennsylvania State University
ex-PDT Partners, McKinsey & Company, PrimeSense, GOI. Columbia Business School MBA 2008, Weizmann Institute of Science MSc 2006
Ex-Escient Pharmaceuticals, Tenaya Therapeutics, FibroGen. Harvard University BS, Caltech PhD 2015
Ben-Gurion University of the Negev PhD 2012
Trethera, ex-Informa, ex-Halozyme Therapeutics, IMD (International Institute for Management Development) - Business Programs, 2006
Co-Founder LUCA Biologics. University of Southern California 2011.
Ritual, ex-Atom Factory, ex-Universal Music, Brown University
61 profiles with education records.
4 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
6,984 articles in the measured 12-month window.
Life Sciences coverage tagged Los Angeles · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 2,179 |
| 2021Q3 | 2,005 |
| 2021Q4 | 1,841 |
| 2022Q1 | 2,125 |
| 2022Q2 | 1,676 |
| 2022Q3 | 1,527 |
| 2022Q4 | 1,671 |
| 2023Q1 | 1,680 |
| 2023Q2 | 2,168 |
| 2023Q3 | 1,690 |
| 2023Q4 | 1,945 |
| 2024Q1 | 2,340 |
| 2024Q2 | 2,792 |
| 2024Q3 | 2,564 |
| 2024Q4 | 2,705 |
| 2025Q1 | 13,982 |
| 2025Q2 | 1,439 |
| 2025Q3 | 1,551 |
| 2025Q4 | 1,986 |
| 2026Q1 | 2,136 |
Article volume measures coverage, not market sales.
294 recorded company events across 26 companies; percentages use that event total.
Life Sciences coverage tagged Los Angeles · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 3,157 | 898 | 252% |
| vaccine trials | 2,962 | 904 | 228% |
| vaccination campaigns | 2,752 | 555 | 396% |
| vaccine immunogenicity | 2,473 | 668 | 270% |
| mass vaccination sites | 2,021 | 272 | 643% |
| vaccination coverage | 1,516 | 202 | 650% |
| vaccine effectiveness study | 1,400 | 251 | 458% |
| angel investors | 1,344 | 590 | 128% |
| covid-19 vaccine development | 1,335 | 238 | 461% |
| pandemic vaccine stockpiling | 1,294 | 242 | 435% |
| investigational new vaccine | 451 | 1,069 | -58% |
| cell-based therapies | 619 | 1,059 | -42% |
| viral vector vaccines | 684 | 1,048 | -35% |
| cancer biomarkers | 670 | 1,040 | -36% |
| diagnostic biotechnology | 570 | 948 | -40% |
United States comparison coverage
core inflation rate, inflation outlook, inflation breakdown
52.8% critical · 34.6% positiveangel investors, vaccine candidates, vaccine trials
49.1% critical · 55.2% positivegdp acceleration, gdp growth rate, economic output growth
49.7% critical · 39.6% positiveLife Sciences coverage tagged Los Angeles. Topic labels describe recorded classifications and can include broad context.
6,260 papers in the recorded india scope.
Tone counts: 5,526 positive · 456 neutral · 278 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro
Common problems researchers identify · 0118.4% of this theme group
Researchers highlight technical hurdles in biochemical engineering, synthetic biology, and nanotech for scalable bioprocesses.
Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)
Microbial Enzymes: Tools for Biotechnological Processes
Medical biofilms
| Year | Share index |
|---|---|
| 2022 | 67.9 |
| 2023 | 70.3 |
| 2024 | 84.4 |
| 2025 | 67.1 |
Common problems researchers identify · 0215.7% of this theme group
Studies flag rising public‑health threats from contaminated produce and persistent food‑borne disease outbreaks.
Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)
The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities
A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments
| Year | Share index |
|---|---|
| 2022 | 301.0 |
| 2023 | 265.8 |
| 2024 | 276.2 |
| 2025 | 304.0 |
Common problems researchers identify · 0315.5% of this theme group
Papers discuss mutation patterns, DNA methylation complexities, and metabolic alterations driving tumor progression.
Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine
| Year | Share index |
|---|---|
| 2022 | 974.1 |
| 2023 | 1199.2 |
| 2024 | 866.8 |
| 2025 | 797.1 |
Common problems researchers identify · 0415.2% of this theme group
Researchers point to difficulties engineering crops for drought, salinity, and other non‑biotic stresses.
Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)
Genetic Engineering for Modern Agriculture: Challenges and Perspectives
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 1472.5 |
| 2023 | 1503.8 |
| 2024 | 1656.9 |
| 2025 | 1839.0 |
Common problems researchers identify · 0514.7% of this theme group
Works emphasize gaps in micronutrient production, biofortification, and safe food‑fermentation practices.
Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)
Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016
Food fermentations: Microorganisms with technological beneficial use
| Year | Share index |
|---|---|
| 2022 | 120.6 |
| 2023 | 117.1 |
| 2024 | 113.1 |
| 2025 | 122.2 |
Common problems researchers identify · 0611.1% of this theme group
Authors raise concerns over growing antimicrobial resistance in clinical and environmental settings.
Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)
An overview of the antimicrobial resistance mechanisms of bacteria
The global threat of antimicrobial resistance: science for intervention
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.5% of this theme group
Studies outline the spread of resistance in insects and challenges for integrated pest‑management strategies.
Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)
Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
| Year | Share index |
|---|---|
| 2022 | 3.4 |
| 2023 | 3.1 |
| 2024 | 4.4 |
| 2025 | 4.3 |
Cautions · 0124.6% of this theme group
Researchers urge caution interpreting DNA repair mechanisms and mutation links in disease contexts.
DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)
Examining the link between chromosomal instability and aneuploidy in human cells
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
| Year | Share index |
|---|---|
| 2022 | 101.2 |
| 2023 | 139.0 |
| 2024 | 91.9 |
| 2025 | 79.2 |
Cautions · 0218.1% of this theme group
Papers caution about unintended immune effects from antibody therapies and peripheral blood cell manipulations.
Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data
| Year | Share index |
|---|---|
| 2022 | 543.7 |
| 2023 | 602.0 |
| 2024 | 448.8 |
| 2025 | 441.1 |
Cautions · 0314.4% of this theme group
Works warn of potential health impacts from nanomaterials and sugar‑related safety issues in food chains.
Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption
| Year | Share index |
|---|---|
| 2022 | 122.8 |
| 2023 | 120.4 |
| 2024 | 118.6 |
| 2025 | 154.1 |
Cautions · 0411.6% of this theme group
Studies highlight uncertainties in trace mineral use and additive impacts on cattle health and methane output.
Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)
Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis
The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst
| Year | Share index |
|---|---|
| 2022 | 126.8 |
| 2023 | 122.4 |
| 2024 | 118.5 |
| 2025 | 129.2 |
Cautions · 0510.8% of this theme group
Authors note challenges in applying genomic selection reliably across diverse crop traits.
Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2367.9 |
| 2023 | 2351.5 |
| 2024 | 2081.1 |
| 2025 | 1566.0 |
Cautions · 0610.5% of this theme group
Research cautions about ecological side‑effects and resistance development in biological control approaches.
PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)
The use of fungal entomopathogens as endophytes in biological control: a review
Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?
| Year | Share index |
|---|---|
| 2022 | 1443.5 |
| 2023 | 1484.3 |
| 2024 | 1642.9 |
| 2025 | 1827.1 |
Cautions · 079.9% of this theme group
Papers stress the risk of resistance spread from veterinary antibiotic practices to human pathogens.
Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)
Multidrug evolutionary strategies to reverse antibiotic resistance
Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Opportunities · 0119.6% of this theme group
Opportunities focus on harnessing beneficial microbes to improve food safety and animal health.
Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)
Probiotics, their health benefits and applications for developing healthier foods: a review
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 2406.7 |
| 2023 | 2240.7 |
| 2024 | 2316.1 |
| 2025 | 1955.8 |
Opportunities · 0219.3% of this theme group
Research explores targeted gene knockdown and apoptosis modulation as promising therapeutic avenues.
Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)
PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development
Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0313.2% of this theme group
Studies highlight advances in T‑cell engineering and antigen targeting for cancer and infectious disease treatment.
Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
| Year | Share index |
|---|---|
| 2022 | 289.3 |
| 2023 | 336.1 |
| 2024 | 224.8 |
| 2025 | 204.1 |
Opportunities · 0412.8% of this theme group
Papers present novel approaches to modify DNA methylation and repair pathways for disease correction.
DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition
| Year | Share index |
|---|---|
| 2022 | 224.2 |
| 2023 | 281.6 |
| 2024 | 196.5 |
| 2025 | 158.4 |
Opportunities · 0512.2% of this theme group
Research showcases multifunctional nanoparticles for real‑time imaging and targeted therapeutic delivery.
In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl
| Year | Share index |
|---|---|
| 2022 | 480.4 |
| 2023 | 520.5 |
| 2024 | 397.5 |
| 2025 | 406.8 |
Opportunities · 0611.7% of this theme group
Works emphasize leveraging germplasm sequencing and diversity analyses to accelerate trait improvement.
Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)
Genotyping‐by‐Sequencing for Plant Breeding and Genetics
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 56.0 |
| 2023 | 51.4 |
| 2024 | 46.1 |
| 2025 | 53.1 |
Opportunities · 0711.3% of this theme group
Studies focus on mRNA and microRNA modulation to control gene expression in health and disease.
Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)
m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc
| Year | Share index |
|---|---|
| 2022 | 229.2 |
| 2023 | 195.8 |
| 2024 | 157.3 |
| 2025 | 136.5 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 32.6% | 26.1% |
| Promising | 31.0% | 37.2% |
| Descriptive | 17.5% | 17.5% |
| Problem-identifying | 9.1% | 9.6% |
| Cautionary | 5.8% | 4.6% |
| Comparative | 2.8% | 4.0% |
| Critical | 1.3% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 18 | 0.3% | 2 (11.1%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 4 | 0.07% | 1 (25.0%) | 0.15% |
| Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis | 3 | 0.05% | 1 (33.3%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 1 | 0.02% | 1 (100.0%) | 0.01% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Compare demand signals in Los Angeles’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Air pollution ↗Environmental Driver | 50.0 | 0.0 | +50.0 | +1.8% | |
| Maternal & child health ↗Disease Burden | 40.0 | 33.3 | +6.7 | +70.7% | |
| Layoffs & income shocks ↗Spending Pressure | 50.0 | 66.7 | -16.7 | +7.2% | |
| Cancer burden ↗Disease Burden | 10.0 | 100.0 | -90.0 | +1.7% | |
| Mental health ↗Disease Burden | 100.0 | — | No matching category | — | +127.9% |
| Ageing & elder care ↗Disease Burden | 50.0 | — | No matching category | — | +41.0% |
Showing all 6 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. Los Angeles is highlighted.
Each city’s reading is a share of its own coverage. Rows cover all of the United States for this page's signal families; Los Angeles is marked.
Layoffs & income shocks · Mental health · Maternal & child health
Layoffs & income shocks · Maternal & child health · Cancer burden
Layoffs & income shocks · Mental health · Maternal & child health
Layoffs & income shocks · Maternal & child health · Air pollution
Maternal & child health · Mental health · Air pollution
Maternal & child health · Layoffs & income shocks · Mental health
Layoffs & income shocks · Air pollution · Mental health
Maternal & child health · Mental health · Layoffs & income shocks
Mental health · Maternal & child health · Layoffs & income shocks
Mental health · Air pollution · Layoffs & income shocks
Maternal & child health · Cancer burden · Mental health
Layoffs & income shocks · Maternal & child health · Mental health
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 25 | 7.56 |
| 2024Q4 | 27 | 7.8 |
| 2025Q1 | 81 | 11.02 |
| 2025Q2 | 39 | 11.34 |
| 2025Q3 | 39 | 10.67 |
| 2025Q4 | 20 | 8.33 |
| 2026Q1 | 19 | 6.6 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 6 | 1.81 |
| 2024Q4 | 5 | 1.45 |
| 2025Q1 | 19 | 2.59 |
| 2025Q2 | 18 | 5.23 |
| 2025Q3 | 28 | 7.66 |
| 2025Q4 | 7 | 2.91 |
| 2026Q1 | 14 | 4.86 |
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 20 | 6.05 |
| 2024Q4 | 39 | 11.27 |
| 2025Q1 | 67 | 9.12 |
| 2025Q2 | 28 | 8.14 |
| 2025Q3 | 50 | 13.67 |
| 2025Q4 | 8 | 3.33 |
| 2026Q1 | 24 | 8.34 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 18 | 5.44 |
| 2024Q4 | 28 | 8.09 |
| 2025Q1 | 25 | 3.4 |
| 2025Q2 | 16 | 4.65 |
| 2025Q3 | 11 | 3.01 |
| 2025Q4 | 7 | 2.91 |
| 2026Q1 | 40 | 13.9 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 43 | 13.0 |
| 2024Q4 | 29 | 8.38 |
| 2025Q1 | 236 | 32.12 |
| 2025Q2 | 23 | 6.69 |
| 2025Q3 | 49 | 13.4 |
| 2025Q4 | 36 | 14.99 |
| 2026Q1 | 427 | 148.36 |
An ageing base can shift demand toward geriatric, home and chronic care.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 16 | 4.84 |
| 2024Q4 | 24 | 6.94 |
| 2025Q1 | 24 | 3.27 |
| 2025Q2 | 24 | 6.98 |
| 2025Q3 | 24 | 6.56 |
| 2025Q4 | 23 | 9.58 |
| 2026Q1 | 16 | 5.56 |
Los Angeles life sciences coverage
MMWR Morbidity and Mortality Weekly Report
273 citations in the snapshot
Ear and Hearing
135 citations in the snapshot
JAMA Internal Medicine
133 citations in the snapshot
MMWR Morbidity and Mortality Weekly Report
129 citations in the snapshot
Los Angeles coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| hospice cancer | 27 | 15 | 156.8% |
| smog reduction | 24 | 17 | 101.4% |
| clean air advocacy | 44 | 44 | 42.7% |
| emissions controls | 24 | 25 | 37.0% |
| pollution control statutes | 22 | 23 | 36.5% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 4 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗